Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Lifco on IPO
Mandate

Vinge advised Lifco on IPO

November 21, 2014

The class B shares of Lifco AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm, following an offering to the general public in Sweden and to institutional investors in Sweden and abroad. The price in the offering was SEK 93 per share, corresponding to a market value of all Lifco shares of approximately SEK 8.4 billion.

Vinge advised Lifco. The Vinge team primarily consisted of Erik Gabrielson, Erik Sjöman, Jesper Schönbeck, Anna Edström and Christian Lindhé, together with a large number of other associates and specialist partners.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026